ESMO 2019: Tailored Approach to Immunotherapy for Advanced Kidney Cancer
Posted: Monday, October 7, 2019
According to the results of the multicentric European TITAN-RCC trial, a tailored approach—first nivolumab alone and then nivolumab plus ipilimumab as an immunotherapeutic boost—may improve responses compared with nivolumab monotherapy. Ongoing follow-up is expected to determine the duration and depth of these responses as well as treatment-related toxicity. These findings were presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract LBA57) by Marc-Oliver Grimm, MD, of Jena University Hospital, Germany, and colleagues.
“TITAN-RCC is the first study to assess the impact of a tailored approach using nivolumab plus ipilimumab as an immunotherapeutic boost [in patients with advanced renal cell carcinoma],” the investigators noted.
A total of 258 patients were enrolled in this study, with 108 patients who received first-line therapy and 99 who received second-line therapy assessed for efficacy. A total of 70% of patients had International Metastatic RCC Database (IMDC) intermediate-risk disease, and 27% had IMDC poor-risk disease.
The investigators reported a 28.7% confirmed objective response rate with first-line nivolumab monotherapy. “Best overall response after nivolumab induction with and without nivolumab plus ipilimumab boosts was 37% and 28% in the first-line and second-line settings, respectively,” they revealed. A total of 102 patients received the immunotherapy boosts for either stable disease (n = 35) or progressive disease (n = 67) until week 16. Of these patients, 12 had a partial or complete response, and 54 had stable disease.
In terms of toxicity, no new safety signals with the combined therapy were reported. In the entire cohort, the rate of grade 3 or 4 adverse events was 30.4%.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.